Boehringer Ingelheim believes that one of its investigational drugs for liver disease hepatitis C (HCV) could shorten patients’ treatment time …
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand
Sterling doubles ADC manufacturing capacity at Welsh facility
Femtosecond laser cuts lung tumour margin assessment time

